Literature DB >> 24429070

Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Benson Ogunjimi1, Evelien Smits, Steven Heynderickx, Johan Van den Bergh, Joke Bilcke, Hilde Jansens, Ronald Malfait, Jose Ramet, Holden T Maecker, Nathalie Cools, Philippe Beutels, Pierre Van Damme.   

Abstract

Reexposure to viruses is assumed to strengthen humoral and cellular immunity via the secondary immune response. We studied the effects of frequent exposure to viral infectious challenges on immunity. Furthermore, we assessed whether repetitive exposures to varicella-zoster virus (VZV) elicited persistently high immune responses. Blood samples from 11 pediatricians and matched controls were assessed at 3 time points and 1 time point, respectively. Besides the assessment of general immunity by means of measuring T-cell subset percentages, antibody titers and gamma interferon (IFN-γ)/interleukin 2 (IL-2)-producing T-cell percentages against adenovirus type 5 (AdV-5), cytomegalovirus (CMV), tetanus toxin (TT), and VZV were determined. Pediatricians had lower levels of circulating CD4(+)-naive T cells and showed boosting of CD8(+) effector memory T cells. Although no effect on humoral immunity was seen, repetitive exposures to VZV induced persistently higher percentages of IFN-γ-positive T cells against all VZV antigens tested (VZV glycoprotein E [gE], VZV intermediate-early protein 62 [IE62], and VZV IE63) than in controls. T cells directed against latency-associated VZV IE63 benefitted the most from natural exogenous boosting. Although no differences in cellular or humoral immunity were found between the pediatricians and controls for AdV-5 or TT, we did find larger immune responses against CMV antigens in pediatricians. Despite the high infectious burden, we detected a robust and diverse immune system in pediatricians. Repetitive exposures to VZV have been shown to induce a stable increased level of VZV-specific cellular but not humoral immunity. Based on our observations, VZV IE63 can be considered a candidate for a zoster vaccine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24429070      PMCID: PMC3957663          DOI: 10.1128/CVI.00818-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  70 in total

1.  Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.

Authors:  K Terada; T Niizuma; Y Yagi; H Miyashima; N Kataoka; T Sadahiro
Journal:  J Med Virol       Date:  2000-09       Impact factor: 2.327

2.  A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia.

Authors:  Kylie S Carville; Michaela A Riddell; Heath A Kelly
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

3.  Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles.

Authors:  M C Schuette; H W Hethcote
Journal:  Bull Math Biol       Date:  1999-11       Impact factor: 1.758

4.  Contacts with children and young people and adult risk of suffering herpes zoster.

Authors:  M Salleras; A Domínguez; N Soldevila; A Prat; P Garrido; N Torner; E Borrás; L Salleras
Journal:  Vaccine       Date:  2011-09-01       Impact factor: 3.641

5.  Lasting immunity to varicella in doctors study (L.I.V.I.D. study).

Authors:  B A Solomon; A G Kaporis; A T Glass; S I Simon; H E Baldwin
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

6.  Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group.

Authors:  A A Gershon; S P Steinberg
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination.

Authors:  Jessica Leung; Rafael Harpaz; Noelle-Angelique Molinari; Aisha Jumaan; Fangjun Zhou
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

8.  Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study.

Authors:  Sara L Thomas; Jeremy G Wheeler; Andrew J Hall
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

9.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.

Authors:  M Brisson; N J Gay; W J Edmunds; N J Andrews
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

Review 10.  Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.

Authors:  Benson Ogunjimi; Pierre Van Damme; Philippe Beutels
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

View more
  18 in total

1.  Cytomegalovirus seropositivity is associated with herpes zoster.

Authors:  Benson Ogunjimi; Niel Hens; Richard Pebody; Hilde Jansens; Holly Seale; Mark Quinlivan; Heidi Theeten; Herman Goossens; Judy Breuer; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling.

Authors:  Giorgio Guzzetta; Piero Poletti; Stefano Merler; Piero Manfredi
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

3.  Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.

Authors:  Adriana Weinberg; Jennifer Canniff; Nadine Rouphael; Aneesh Mehta; Mark Mulligan; Jennifer A Whitaker; Myron J Levin
Journal:  J Immunol       Date:  2017-06-12       Impact factor: 5.422

4.  Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia.

Authors:  Pieter Meysman; Benson Ogunjimi; Stefan Naulaerts; Philippe Beutels; Viggo Van Tendeloo; Kris Laukens
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

5.  Altered CD4+ T cell immunity in nurses occupationally exposed to viral pathogens.

Authors:  G Elias; A Souquette; S Heynderickx; I De Meester; H Jansens; P Beutels; P Van Damme; E Smits; P G Thomas; V Van Tendeloo; B Ogunjimi
Journal:  Clin Exp Immunol       Date:  2018-09-19       Impact factor: 4.330

6.  Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly.

Authors:  Heidi Theeten; Catharina Mathei; Kelly Peeters; Benson Ogunjimi; Herman Goossens; Margareta Ieven; Pierre Van Damme; Nathalie Cools
Journal:  Viral Immunol       Date:  2016-03-22       Impact factor: 2.257

7.  Increasing trends of herpes zoster in Australia.

Authors:  Raina MacIntyre; Alicia Stein; Christopher Harrison; Helena Britt; Abela Mahimbo; Anthony Cunningham
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

8.  The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study.

Authors:  Valentina Marziano; Piero Poletti; Giorgio Guzzetta; Marco Ajelli; Piero Manfredi; Stefano Merler
Journal:  Proc Biol Sci       Date:  2015-04-07       Impact factor: 5.349

9.  Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.

Authors:  Pieter Meysman; Nicolas De Neuter; Esther Bartholomeus; George Elias; Johan Van den Bergh; Marie-Paule Emonds; Geert W Haasnoot; Steven Heynderickx; Johan Wens; Nele R Michels; Julien Lambert; Eva Lion; Frans H J Claas; Herman Goossens; Evelien Smits; Pierre Van Damme; Viggo Van Tendeloo; Philippe Beutels; Arvid Suls; Geert Mortier; Kris Laukens; Benson Ogunjimi
Journal:  Immunogenetics       Date:  2017-12-01       Impact factor: 3.330

10.  Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster.

Authors:  Benson Ogunjimi; Lander Willem; Philippe Beutels; Niel Hens
Journal:  Elife       Date:  2015-07-11       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.